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ARTICLE
Identiﬁcation and characterization of two functional
variants in the human longevity gene FOXO3
Friederike Flachsbart1, Janina Dose1, Liljana Gentschew1, Claudia Geismann2, Amke Caliebe3, Carolin Knecht3,
Marianne Nygaard4, Nandini Badarinarayan1, Abdou ElSharawy1,5, Sandra May1, Anne Luzius1,
Guillermo G. Torres1, Marlene Jentzsch1, Michael Forster1, Robert Häesler1, Kathrin Pallauf6, Wolfgang Lieb7,
Céline Derbois8, Pilar Galan9, Dmitriy Drichel10, Alexander Arlt 2, Andreas Till 1,11, Ben Krause-Kyora 1,12,
Gerald Rimbach6, Hélène Blanché 13, Jean-François Deleuze8,13, Lene Christiansen4, Kaare Christensen4,14,
Michael Nothnagel10, Philip Rosenstiel1, Stefan Schreiber1,2, Andre Franke 1, Susanne Sebens15 & Almut Nebel1
FOXO3 is consistently annotated as a human longevity gene. However, functional variants
and underlying mechanisms for the association remain unknown. Here, we perform
resequencing of the FOXO3 locus and single-nucleotide variant (SNV) genotyping in three
European populations. We ﬁnd two FOXO3 SNVs, rs12206094 and rs4946935, to be most
signiﬁcantly associated with longevity and further characterize them functionally.
We experimentally validate the in silico predicted allele-dependent binding of transcription
factors (CTCF, SRF) to the SNVs. Speciﬁcally, in luciferase reporter assays, the longevity
alleles of both variants show considerable enhancer activities that are reversed by IGF-1
treatment. An eQTL database search reveals that the alleles are also associated with higher
FOXO3 mRNA expression in various human tissues, which is in line with observations in long-
lived model organisms. In summary, we present experimental evidence for a functional link
between common intronic variants in FOXO3 and human longevity.
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Human longevity is a complex phenotype with modestheritability1. The identiﬁcation of the involved genes andvariants still remains a challenge even though the ﬁrst
ever genetic association of the apolipoprotein E allele ε4 with
longevity was already reported in 19942. Since then, this ﬁnding
has been replicated in numerous studies3,4. Variation in the
forkhead box O3 (FOXO3) gene is the only other consistent factor
that was shown to inﬂuence longevity across diverse populations,
including Japanese-Americans5, Germans6, and Danes7. Inter-
estingly, the effect of the FOXO3 association is very strong in
long-lived individuals (LLI) beyond 95 years of age, and especially
in centenarians6. Although FOXO3 is consistently annotated as a
human longevity gene, the functional variants and the underlying
mechanisms have not been identiﬁed yet. The large majority of
associated single-nucleotide variants (SNVs) are located in the 3′-
UTR of the gene and cluster in or near the last intron6. Pre-
liminary sequence analyses indicate that FOXO3 coding variants
are unlikely to play a role in longevity8–10. This observation is
supported by the fact that the transcription factor FOXO3 is
evolutionarily highly conserved11. FOXO3 regulates the insulin
receptor/insulin-like growth factor-I signaling (IIS) pathway12
and is, amongst others, involved in energy metabolism, oxidative
stress, apoptosis, cell-cycle regulation and stem cell homeostasis
(reviewed in ref. 13). Genetic manipulations of FOXO3 orthologs
lead to lifespan extension in various model organisms, mainly via
an increased expression of the gene (reviewed in refs 14,15).
Enhanced FOXO3 transcription may also mediate a similar
beneﬁcial effect in humans13,16. In addition, FOXO3 activity or
expression can be modulated by dietary interventions like dietary
restriction17,18 and phytochemicals such as epigallocatechin gal-
late (EGCG) in green tea19.
The aim of the present study was to identify and characterize
functional variants in the FOXO3 gene. We report on the
characterization of the two associated SNVs rs12206094
and rs4946935 that were detected after resequencing of the
FOXO3 gene and association testing in German, French, and
Danish longevity samples. We validate in silico predicted SNV
allele-dependent binding of transcription factors (CTCF, SRF)
experimentally. Luciferase reporter assays show enhancer activ-
ities for the longevity alleles of both SNVs, which are reversed by
insulin-like growth factor 1 (IGF-1) treatment. An expression
quantitative trait loci (eQTL) database search reveals SNV allele-
speciﬁc associations with FOXO3 mRNA expression. Overall, our
data provide evidence for a functional link between common
intronic variants in FOXO3 and the longevity phenotype in
humans.
Results
Resequencing and ﬁne-mapping of the FOXO3 gene. For the
detection of common and rare variants, the whole FOXO3 gene
region was resequenced using two next-generation sequencing
(NGS) technologies—sequencing by ligation (SBL, SOLiD) and
sequencing by synthesis (SBS, Illumina)—and the Sanger method
in a total of 118 German LLI (99–110 years), 152 younger Ger-
man controls (60–75 years) and six HapMap-CEU individuals.
The samples used for the different sequencing technologies are
provided in Supplementary Table 1. SBL and SBS resulted in a
total of 1,081 unique SNV calls with an overlap of 293 SNVs
(Supplementary Figs. 1 and 2). Sanger sequencing of the pro-
moter, the exons and exon-intron boundaries led to the detection
of 42 SNVs. As 17 of these SNVs had already been observed by
NGS, the total number of variants amounted to 1,106 (Supple-
mentary Data 1, Supplementary Fig. 2).
Subsequently, for a comprehensive ﬁne-mapping of the FOXO3
gene region, 205 of the detected 1,106 SNVs were analyzed
(Supplementary Data 1). These SNVs were either (i) located in
regulatory regions (e.g. sites for microRNA binding, DNA
methylation or transcription factor binding), (ii) selected through
a haplotype-tagging approach or (iii) identiﬁed in the exonic
regions. The SNVs were investigated in the German case–control
sample for association with longevity. Fifty-four nominally
statistically signiﬁcant SNVs (P< 0.05) were detected both in
the whole German longevity sample (1109 LLI, 95–110 years) and
in the smaller subset of 594 centenarians (100–110 years) vs. 918
younger controls (60–75 years) (Supplementary Data 2). As
expected, individuals aged 100 years and older yielded larger odds
ratios (OR) compared with the younger longevity sample (≥ 95
years; Table 1; Supplementary Data 2). Correction for multiple
testing was not deemed necessary since FOXO3 is already a
conﬁrmed longevity gene and since the aim of the association
approach was to identify the most promising potentially
functional variants. Four of the 54 nominally signiﬁcant SNVs
were located in the non-coding exon 4 (smallest P value = 0.003 in
the centenarian subsample) (Supplementary Data 2). The in silico
analysis with MutationTaster220 did not predict any speciﬁc
effects for the SNVs in exon 4. Thus, they were not considered for
subsequent functional studies. The association signals with the
smallest P values were observed for the two intronic SNVs
rs4946935 (Pcent = 0.0003, OR = 1.35) and rs12206094 (Pcent =
0.001, OR = 1.31; Table 1, Fig. 1); therefore, these two SNVs were
investigated in more detail. Both are common SNVs, with minor
allele frequencies of about 30% in controls and up to 37% in
centenarians (Table 1). Based on transcript NM_201559, SNV
rs12206094 is located in the second, and rs4946935 in the third
(=last) intron of FOXO3 (Fig. 1). Although the two SNVs are
94.5 kb apart from each other, they are in moderate LD (r2 = 0.61
based on HapMap-CEU individuals, 1000 Genomes21,22). In a
model incorporating both SNVs, a signiﬁcant negative interaction
Table 1 Association statistics for the FOXO3 SNVs
rs4946935 and rs12206094 in the whole German study
population and centenarian subpopulation
SNV Study
population
MAFa
LLI
MAFa
Controls
PCCAb ORc 95% C.I.d
Whole study population
rs4946935
Total 0.349 0.304 0.003 1.228 1.072–1.406
Female 0.350 0.313 0.037 1.181 1.010–1.381
Male 0.347 0.278 0.022 1.375 1.046–1.808
rs12206094
Total 0.325 0.287 0.010 1.196 1.044–1.369
Female 0.322 0.291 0.068 1.157 0.989–1.353
Male 0.333 0.275 0.045 1.318 1.006–1.726
Centenarian subpopulation
rs4946935
Total 0.370 0.304 0.0003 1.345 1.147–1.577
Female 0.372 0.313 0.004 1.303 1.088–1.559
Male 0.360 0.278 0.032 1.458 1.032–2.060
rs12206094
Total 0.345 0.287 0.001 1.306 1.116–1.529
Female 0.342 0.291 0.011 1.261 1.055–1.508
Male 0.357 0.275 0.024 1.469 1.052–2.050
Listed are allele frequencies, allelic P values, odds ratios, and the 95% conﬁdence intervals for
the whole study population and centenarian subpopulation (1109 LLI≥ 95 years including 594
centenarians, 918 younger controls (age range: 60–75 years)). The statistics are listed for all
individuals of the study populations as well as for males and females separately (males: 275
LLI≥ 95 years including 119 centenarians, 237 younger controls; females: 834 LLI≥ 95 years
including 475 centenarians, 681 younger controls)
a Minor allele frequency, MAF; the deﬁnition of the minor allele is based on controls; minor
alleles are A for rs4946935 and T for rs12206094
b Allelic P values, PCCA; calculated with chi-squared test with one degree of freedom
c Odds ratio for longevity, OR; based on the minor allele in controls
d 95% conﬁdence interval, 95% C.I.; C.I. for the odds ratio
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between them was found (Table 2; genotype model: P = 0.0011,
allelic model: P = 0.000018). The ORs for combinations of
the favorable longevity (minor) alleles were much reduced
due to the interaction effect. It follows that being homozygous
for the favorable allele of one SNV and for the unfavorable allele
(major) of the other SNV is more advantageous than being
heterozygous or even homozygous for the favorable allele of both
SNVs. Using the 1000 Genomes Pilot 1 data21,22, we estimated
the LD between our two variants and rs10457180 which was
previously reported to be the most robustly longevity-associated
SNV in FOXO34. While rs12206094 only showed modest LD with
rs10457180 (r2 = 0.64), the LD between rs10457180 and
rs4946935 was stronger (r2 = 0.92). In Supplementary Data 2,
rs10457180 is listed as one of the 54 associated SNVs; however, it
had a smaller OR (OR = 1.171 in German LLI vs. younger
controls) than our two top-associated SNVs. Therefore, it may
well be that the effects of rs4946935 and rs12206094 were tagged
by rs10457180.
Replication of associations for rs4946935 and rs12206094. The
associations for rs4946935 and rs12206094 were conﬁrmed in a
French sample (1,264 LLI, 91–115 years; 1,830 younger controls,
35–62 years) with P= 0.022 (OR = 1.14) and P = 0.008 (OR =
1.16), respectively (Table 3). In a smaller Danish sample (643 LLI,
92–101 years; 746 younger controls, 56–71 years), the signal at
rs12206094 replicated as well (P= 0.012, OR = 1.24) and the
allelic effect of rs4946935, though not statistically signiﬁcant,
showed the same trend as in the French and German individuals
(P= 0.127, OR = 1.14; Table 3). A meta-analysis of all three study
populations strengthened the associations (Table 3). The asso-
ciation signals at both SNVs consistently had a higher estimated
OR in males than in females (Table 1, Table 3); this difference
was signiﬁcant for rs12206094 in the meta-analysis (P = 0.042),
but not for rs4946935 (P = 0.218). A similar observation was
already reported before7. The biological implications of these
ﬁndings remain to be clariﬁed.
In addition, we evaluated associations of both SNVs with age-
related phenotypes in the Danish study sample (Supplementary
Tables 2–5), for which this information was available. Some
nominally signiﬁcant association results were observed (Supple-
mentary Tables 2 and 4). However, after correction for multiple
testing, none of them remained signiﬁcant. When taking into
consideration all-cause mortality, none of the identiﬁed SNVs
showed a signiﬁcant association. This lack of association with
mortality indicates that the two loci contribute to reaching old
age, but not to escaping mortality among the extremely long-
lived, at least not in the Danish population. This observation is
supported by a previous study7.
Given the strong and validated associations for rs4946935 and
rs12206094 with longevity, we decided to examine the functional
inﬂuence of these two intronic SNVs.
SNV allele-speciﬁc transcription factor binding afﬁnities.
Bioinformatic analysis suggested allele-speciﬁc transcription fac-
tor binding for rs4946935. The tool sTRAP23 (http://trap.molgen.
mpg.de/cgi-bin/trap_two_seq_form.cgi) predicted a high binding
afﬁnity of the longevity allele A to serum response factor (SRF, P
= 6.02E − 06, log afﬁnity value 3.37) and of the major allele G to
pancreatic and duodenal homeobox 1 (PDX1, P= 6.02E − 06, log
afﬁnity value 4.38). These values for rs4946935 were the most
signiﬁcant ones amongst all 54 nominally associated variants
when tested with sTRAP. HaploReg v4.124 and RegulomeDB
v1.125 conﬁrmed the sTRAP predictions only for SRF and the A-
allele, not for PDX1 and the G-allele. We examined several tissues
and cell lines for co-expression of the transcription factors
FOXO3, SRF, and PDX1 and selected the Panc1 cell line (human
pancreatic ductal epithelioid carcinoma cells) as our cellular
model, according to the observed expression results (Supple-
mentary Fig. 3). Subsequently, we tested the in silico prediction
Chromosomal position in kb
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
108940000 108990000 109040000 109090000 109140000
–
Lo
g 1
0P
CC
A
Significance threshold
rs12206094 
(C/T)
rs4946935 
(A/G)
FOXO3
NM_201559
1 2 3 4
Fig. 1 Association plot shows all 205 SNVs tested in the FOXO3 gene region on chromosome 6 (hg18). The two SNVs with the best P values are indicated
(red circles). The four exons are shown in the gene model. Number of individuals: 594 German long-lived individuals (≥100 years) and 918 controls
(60–75 years). PCCA, allelic P values, determined in a case–control association study by chi-squared test with one degree of freedom; −log10PCCA, negative
decadic logarithm of allelic P values
Table 2 Odds ratios of the combined genotypes of
rs12206094 and rs4946935
rs12206094
CC CT TT
rs4946935 GG 1, n= 550 1.81, n= 107 3.27, n= 2
AG 1.81,
n= 69
1.92 (3.28), n= 517 2.04 (5.92), n= 35
AA 3.29,
n= 7
2.05 (5.95), n= 28 1.28 (10.76),
n= 104
Given are the odds ratios (ORs) for the allelic interaction model (multiplicative OR scale). In
brackets are the theoretic combined ORs if no interaction were present (given the same single
SNV ORs). The underlying population is the German longevity sample with 594 centenarians
and 918 younger controls. n = number of individuals
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experimentally by electrophoretic mobility shift assay (EMSA).
Appearance of a DNA/protein complex speciﬁc for rs4946935-A
validated the predicted binding of the transcription factor SRF to
the DNA sequence containing rs4946935-A (Fig. 2a). Supershift
of this complex by addition of anti-SRF antibody (indicated
as “supershift”) speciﬁcally conﬁrmed the presence of SRF in
the detected DNA/protein complex. Consistent with this result,
a binding of SRF to rs4946935-A was also observed in the human
T cell leukemia lymphoblast cell line Jurkat (Fig. 2b). As expected
from the bioinformatic analysis, no such binding to the
major allele G was observed (Fig. 2). Furthermore, neither did
the EMSA experiments in Panc1 cells show binding of the
transcription factor PDX1 to the DNA sequence containing
rs4946935-G or rs4946935-A (Fig. 2a).
For rs12206094, only the tool sTRAP23 suggested
binding, albeit weak, of the signal transducer and activator
of transcription 5 A (STAT5A) to the minor longevity allele (T)
(P= 0.0001, log afﬁnity value −2.03). Since Jurkat cells do
not express STAT5A (Supplementary Fig. 3), the potential
binding was tested in Panc1 cells only. However, supershift
experiments with an STAT5A antibody did not show any
binding of STAT5A to the DNA sequence containing
rs12206094-C or rs12206094-T (Supplementary Fig. 4a, b). It
should be noted that we cannot rule out the possibility that other
Table 3 Association statistics for the SNVs rs4946935 and rs12206094 in the French and Danish replication cohorts,
respectively
SNV Study population MAFa LLI MAFa Controls PCCAb ORc 95% C.I.d
rs4946935
French Total 0.324 0.297 0.022 1.136 1.018–1.268
Female 0.318 0.294 0.094 1.118 0.981–1.274
Male 0.355 0.302 0.032 1.273 1.020–1.589
Danish Total 0.304 0.278 0.127 1.137 0.964–1.340
Female 0.308 0.296 0.568 1.059 0.870–1.289
Male 0.290 0.248 0.183 1.237 0.905–1.691
Meta-analysis: German, French, Danish Total 0.329 0.295 2.38E−05 1.188 1.097–1.287
Female 0.327 0.300 0.003 1.154 1.050–1.267
Male 0.336 0.285 0.001 1.305 1.110–1.535
rs12206094
French Total 0.326 0.294 0.008 1.160 1.040–1.295
Female 0.317 0.291 0.064 1.131 0.993–1.289
Male 0.364 0.298 0.008 1.345 1.079–1.677
Danish Total 0.305 0.262 0.012 1.235 1.047–1.458
Female 0.302 0.282 0.328 1.104 0.905–1.346
Male 0.315 0.232 0.008 1.527 1.118–2.085
Meta-analysis: German, French, Danish Total 0.325 0.285 1.31E−06 1.219 1.125–1.321
Female 0.319 0.289 0.002 1.164 1.059–1.280
Male 0.348 0.278 1.49E−05 1.426 1.215–1.675
Listed are allele frequencies, allelic P values, odds ratios, and the 95% conﬁdence intervals for the whole study populations (1264 LLI≥ 91 years and 1830 younger controls (35–62 years) from France and
643 LLI≥ 92 years and 746 younger controls (56–71 years) from Denmark) as well as for the subgroups of females (1032 LLI and 1,105 younger controls from France and 493 LLI and 456 younger
controls from Denmark) and males (232 LLI and 725 younger controls from France and 150 LLI and 290 younger controls from Denmark)
a Minor allele frequency, MAF; the deﬁnition of the minor allele is based on controls; minor alleles are A for rs4946935 and T for rs12206094
b Allelic P values, PCCA; calculated with chi-squared test with one degree of freedom
c Odds ratio for longevity, OR; based on the minor allele in controls
d 95% conﬁdence interval, 95% C.I.; C.I. for the odds ratio
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Fig. 2 SRF binds to the longevity allele A but not to the major allele G of rs4946935. Nuclear extracts from Panc1 a and Jurkat b cells were submitted to
EMSA with the indicated oligonucleotides. Supershift experiments were performed with antibodies as listed. The position of the supershifted complex is
indicated by an arrow. One biological replicate of four is shown. Gt goat, IgG immunoglobulin G, NC nonspeciﬁc control (NC I: anti-STAT5A, rabbit; NC II:
anti-PDX1, rabbit; NC III, anti-PDX1, goat); PDX1 pancreatic and duodenal homeobox 1, rb rabbit, SRF serum response factor
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Fig. 3 FOXO3 SNVs rs12206094 and rs4946935 inﬂuence luciferase promoter activity, and knockdown of SRF links this transcription factor to rs4946935.
a, b Luciferase promoter assays were perfomed in Panc1 cells transfected with allele-speciﬁc constructs for rs12206094 (a) and rs4946935 (b) in both the
presence and absence of FCS. For both SNVs, the promoter activity in cells transfected with constructs containing the respective major allele was set = 1
(black dot). Each white dot represents one independent experiment (n = 5). The tables below the ﬁgures show the median as well as the minimum and
maximum values for the ratio of the longevity allele to the respective alternative allele, taking into account all experiments. c, d Knockdown of transcription
factors was done using speciﬁc siRNAs. The luciferase activity in cells treated with control siRNA (con siRNA) instead of the transcription factorspeciﬁc
siRNA was set = 1 (black dot) for each allele of each SNV. Each white dot represents one independent experiment (n = 5). The tables below the ﬁgures
show the median as well as the minimum and maximum values for the ratios of the activity in presence of con siRNA and transcription factor-speciﬁc
siRNA for each allele, taking into account all experiments. a–d For determination of speciﬁc luciferase activity, activity of the ﬁreﬂy luciferase was
normalized to the activity of the renilla luciferase. P ≤ 0.05 was considered statistically signiﬁcant (two-sided Wilcoxon signed-rank test for paired data).
A.U., arbitrary luminescence units
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STAT family proteins with similar consensus binding sites bind
to this sequence.
According to the Ensembl gene annotation system26,
rs12206094 is located within a CCCTC-binding factor (CTCF)
binding site. Upload of FOXO3 sequences containing rs12206094-
C or rs12206094-T to the CTCF binding site database
(CTCFBSDB) 2.027 conﬁrmed a potential binding site for CTCF
when the rs12206094-C allele is present. In contrast, the
prediction of a CTCF binding site was much weaker for
rs12206094-T (Supplementary Table 6). In EMSA experiments
using nuclear extracts from Jurkat cells, CTCF binding to the
oligonucleotide containing the rs12206094-C allele (Supplemen-
tary Fig. 5a, lane 1, right gel) was stronger than to the
rs12206094-T-oligonucleotide (Supplementary Fig. 5a, lane 1,
left gel). Speciﬁcity of CTCF binding was conﬁrmed by supershift
experiments (Supplementary Fig. 5a, lane 3). Densitometric
quantiﬁcation of the speciﬁc bands against loading control
conﬁrmed these observations in four independent experiments
(Supplementary Fig. 5b). Despite considerable CTCF expression
(Supplementary Fig. 3), no DNA binding of CTCF was observed
in Panc1 cells.
SNV allele-speciﬁc inﬂuence on promoter activity. To investi-
gate whether rs4946935 and rs12206094 inﬂuence promoter
activity in an allele-speciﬁc manner, luciferase promoter assays
with SNV-speciﬁc reporter constructs were performed in Panc1
and Jurkat cells. For both SNVs, luciferase assays showed sig-
niﬁcantly enhanced promoter activity in Panc1 cells transfected
with constructs containing the minor (=longevity) alleles com-
pared with constructs containing the major alleles (P< 0.05)
(Fig. 3a, b). This effect was seen both in the presence and absence
of fetal calf serum (+/−FCS), the latter mimicking nutrient
deprivation (Fig. 3a, b). Similar results were observed in Jurkat
cells (Supplementary Fig. 6a, b).
To study whether promoter activation by EGCG occurs
in an allele-speciﬁc manner (as mentioned above, EGCG
was shown to modulate FOXO3 expression19), Panc1 and
Jurkat cells were transfected with either of the four different
FOXO3 luciferase constructs and additionally treated with
EGCG (50 µM). An enhancing effect of this treatment was
observed in the absence of FCS for rs12206094-T in both cell
lines, reaching statistical signiﬁcance in Jurkat cells (Supplemen-
tary Fig. 7a, c).
To validate that the enhancing effects of the longevity alleles
on promoter activity were in fact mediated by allele-speciﬁc
binding of SRF and CTCF, respectively, we performed luciferase
assays with Panc1 cells after siRNA-mediated knockdown of
either transcription factor (for veriﬁcation of the knockdown refer
to Supplementary Fig. 8). For rs12206094, no allele-speciﬁc effect
of the CTCF knockdown on luciferase promoter activity was
evident (Fig. 3c). However, in cells transfected with either
rs4946935-A or -G, knockdown of SRF reduced the promoter
activity when the longevity allele A was present (P< 0.05;
Fig. 3d).
To further investigate the previously reported link between
FOXO3, IGF-1 levels, and longevity28, we treated Panc1 cells
(being transfected with either promoter construct and cultured
under FCS-deprived conditions) with 100 ng/mL IGF-1. Inter-
estingly, the longevity alleles of both SNVs appeared more
susceptible to IGF-1 treatment in terms of a reduced promoter
activity than the respective major alleles, which remained rather
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Fig. 4 IGF-1 treatment reduces luciferase promoter activity in the presence of the longevity alleles of rs12206094 and rs4946935, respectively. a, b
Luciferase promoter assays were perfomed in Panc1 cells transfected with allele-speciﬁc constructs for rs12206094 (a) and rs4946935 (b). The activity of
cells treated with DMSO as control instead of IGF-1 was set = 1 (black dot) for each allele of each SNV. Each white dot represents one independent
experiment (n = 6). Final DMSO concentrations did not exceed 0.1%. The tables below the ﬁgures show the median as well as the minimum and maximum
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signiﬁcant (two-sided Wilcoxon signed-rank test for paired data). A.U., arbitrary luminescence units
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unresponsive (Fig. 4a, b). Since both SNVs showed the same
direction of effect to IGF-1 treatment in our experiments,
different mechanisms may mediate this response.
Stimulation with insulin did, in contrast to IGF-1 treatment,
not induce consistent allele-speciﬁc effects on promoter activity
neither at high nor at low concentrations (1 µg/mL and 10 µg/mL,
respectively; Supplementary Fig. 9).
SNV-eQTL associations. To examine whether rs12206094 and
rs4946935 or SNVs in LD (r2> 0.8 based on HapMap-CEU
individuals, 1000 Genomes21,22) inﬂuenced FOXO3 gene
expression, the publicly available Blood eQTL browser29 (http://
genenetwork.nl/bloodeqtlbrowser/) and the GTEx eQTL database
(http://www.gtexportal.org/home/) were queried. Using the “Test
Your Own SNP-Gene Associations” section of the GTEx database,
which allows searching for associations between a certain SNV
and a gene of interest, we observed statistically signiﬁcant eQTL
associations between FOXO3 and rs12206094 or rs4946935 in
various tissues (several brain regions, pancreas, prostate, testis;
Supplementary Table 7). For almost all signiﬁcant eQTLs, FOXO3
mRNA expression was higher in the presence of the longevity
(minor) alleles for both SNVs (Supplementary Table 7, Supple-
mentary Fig. 10). Further signiﬁcant cis eQTL associations out-
side the FOXO3 gene region were observed for both of the two
SNVs or their LD-SNVs in diverse human tissues including blood
(Supplementary Table 7).
SNV allele distributions worldwide. The longevity-associated T-
allele of rs12206094 (C/T) represents the derived status and is less
frequent than the ancestral C-allele in all investigated populations
from the 1000 Genomes Project22 (Supplementary Table 8). In
contrast, rs4946935 (A/G), with A being both the ancestral and
longevity-enabling allele, showed a markedly different distribu-
tion. In particular, frequencies between 63.6% and >90% for the
A-allele in Subsaharan African populations contrasted with fre-
quencies less than 50% in all non-African populations, namely
26.5–34.1% in Europeans and 17.1–19.2% in Asians (Supple-
mentary Table 8), yielding substantial ﬁxation indices (e.g., FST
value 0.48 for CEU vs. LWK and 0.68 for CEU vs. YRI; http://
jjwanglab.org/dbpshp)30. Such differences may be indicative of
either a past selection event, possibly during the initial out-of-
Africa migration, or ongoing selection. However, investigation of
possible selection in the FOXO3 gene region yielded inconclusive
results. Tajima’s D values (measuring the degree of deviation
from neutral evolution), which are based on a single-variant
single-population assessment, ranged between 0.96–2.09 and
1.61–3.57 for rs12206094 and rs4946935, respectively, in Eur-
opeans from the 1000 Genomes Project22 and were substantially
higher than those in the East Asian and African populations
(Supplementary Table 9). These values in Europeans are con-
sistent with balancing or diversifying selection, but may also
mirror a sudden population contraction or one or more admix-
ture events in the past. However, Tajima’s D values for
rs12206094 and rs4946935 were by no means exceptional in the
light of the general upward shift of Tajima’s D values in all
investigated populations (Supplementary Fig. 11, Supplementary
Table 9).
Discussion
In the present study, we report on the functional characterization
of the two intronic FOXO3 SNVs rs4946935 (A/G) and
rs12206094 (C/T). The two SNVs yielded the strongest associa-
tion signals for longevity in the German sample and were
therefore chosen for replication in French and Danish longevity
collections and functional follow-up studies. Both rs4946935 and
rs12206094 were also signiﬁcantly associated with longevity in the
French sample examined here. This is especially re-assuring as in
a previous study, three FOXO3-longevity associations observed in
Germans could not be conﬁrmed in French. However, these
discrepancies were most likely due to the much smaller French
sample (535 centenarians vs. 553 controls) used at that time6. In
the investigated Danish sample (of likewise modest size),
rs12206094 replicated as well, whereas results for rs4946935 were
supportive but did not reach statistical signiﬁcance. Nevertheless,
rs4946935 was earlier reported to be associated with longevity in
Ashkenazi Jewish centenarians and US American women of
European ancestry8. In an epidemiological cohort study of white
US Americans (aged ≥ 65 years), carriers of the rs4946935-AA
genotype had an increased lifespan compared to those with the
GA or the GG genotype (1.2 and 1.6 years, respectively)31. In the
LLI investigated here, the ORs for the two SNVs were, as
expected, relatively small (Tables 1 and 3), suggesting a rather
modest effect that increased substantially in the subset of cen-
tenarians. In addition, both FOXO3 longevity alleles had a higher
estimated OR in males; especially rs12206094-T showed a very
strong effect in nonagenarian and centenarian men as observed
previously in a Danish sample partly overlapping with the one
analyzed here7.
The analysis of the two top-associated SNVs with regard to
age-related phenotypes in the Danish study population (Supple-
mentary Table 5) yielded no signiﬁcant associations after cor-
rection for multiple testing (Supplementary Tables 2–4). Basic
cognitive and physical measures like the cognitive composite
score, the Mini-Mental State Examination (MMSE) and chair
stand are generally known to show considerable variation in the
oldest-old and are predictive of survival32. The fact that we did
not observe any robust signiﬁcant associations for these pheno-
types with our variants may be a consequence of limited sample
size. However, some nominally signiﬁcant associations were
detected that could be worth following up in larger sample col-
lections in future studies.
In model organisms, the suppression of the IIS pathway seems
to be the most efﬁcient intervention to extend lifespan33. The IIS
reduction is coupled to the expression of various members of the
FOXO protein family (reviewed in refs 14,15,33). It has been
hypothesized that a similar mechanism may also operate in
humans, likely involving FOXO313,16. Our luciferase promoter
assays with SNV-speciﬁc reporter constructs showed that the
minor alleles of rs4946935 and rs12206094, which were more
common in centenarians, both considerably enhanced promoter
activity in Panc1 and Jurkat cells. Thus, it may be possible that
rs4946935-A and rs12206094-T each lead to a reduction in IIS.
Surprisingly, when both longevity (minor) alleles were present in
the same individual, they genetically interacted in a negative
manner, showing much smaller ORs than if they acted inde-
pendently (Table 2). In future experiments, the interaction effect
could be investigated in cells that differ only in the bases at the
two SNV positions. These cells might be generated by gene
editing with CRISPR/cas9. It is conceivable that due to the
combined effect of both longevity alleles on the IIS, the activity of
this pathway may be too low to support survival into old age at
the best possible rate. Moreover, these two SNVs are probably not
the only functionally relevant variations in FOXO3. In line with
our results, it has already been suggested that a ﬁne-tuned opti-
mal range of IIS is needed for longevity34.
Interestingly, also under limited nutrient availability (i.e.,
absence of FCS in our cell culture models), the longevity alleles of
both SNVs caused a higher promoter activity than the major
alleles. FOXO3 is a sensor of nutrient stress13 and adverse
environmental stimuli (dietary restriction, absence of IGF-1,
insulin or growth factors) are known to lead to an increased
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activity or expression of FOXO3 and its target genes in various
model systems17,35–37, ultimately ensuring survival and thus
longevity13.
In addition, our luciferase promoter studies revealed that, at
least in case of rs12206094, treatment with EGCG may further
enhance promoter acitivities, substantiating the observation that
FOXO3 can be activated by this tea component19. In our
experimental set-up, the effect of EGCG on promoter activity was
observed under FCS-deprived culture conditions. This could, at
least in part, be due to the ﬂavonoid EGCG being bound to serum
components in the presence of FCS38.
The G to A transition of SNV rs4946935 created a binding site
for the transcription factor SRF, which we conﬁrmed experi-
mentally. Our knockdown experiments in Panc1 cells transfected
with the rs4946935 allele-speciﬁc constructs showed that the
enhancing activity of the longevity allele A is mediated by SRF.
Interestingly, SRF regulates Igf-1 expression in various mouse
tissues39,40, likely through direct binding of SRF to the Igf-1
promoter39. Tissue-speciﬁc disruption of the Srf gene leads to
signiﬁcant reductions in IGF-1 serum levels39,40. MatInspector
analysis41 revealed SRF binding sites in the human IGF-1 pro-
moter. Therefore, the binding site in the FOXO3 intron may
compete with that in the IGF-1 promoter for SRF and thus could
also inﬂuence IGF-1 expression. The minor allele of rs2153960, an
SNV in strong LD with rs4946935 in Europeans (r2 = 0.96 based
on HapMap-CEU individuals21,22), was shown to be associated
with both lower serum concentrations of IGF-1 and IGF binding
protein 3 (IGFBP-3) as well as with survival beyond 90 years28,42.
However, to which degree rs4946935-A exerts its effect on life-
span via SRF-binding and eventually lower circulating IGF-1
remains to be clariﬁed.
The CTCF supershift experiments indicated a slightly stronger
binding of CTCF to the oligonucleotide containing the major
allele C of rs12206094, conﬁrming the CTCFBSDB 2.027 predic-
tion. However, our functional experiments with the rs12206094
allele-speciﬁc constructs suggested that the binding strength of
CTCF did not inﬂuence the luciferase promoter activity. The
factor underlying this observation is as yet unclear. Literature
data, however, supports a link between FOXO3 and CTCF
binding sites. In 2007, Xie et al.43 discovered highly conserved
CTCF binding motifs that have regulatory functions. A C→ T
mutation in one particular motif called LM23, which is very
similar to our investigated CTCF binding site, was reported to
lead to a considerable reduction in CTCF binding afﬁnity43. The
C→ T transition at rs12206094 may have the same effect. In view
of the diverse functions of CTCF, including transcriptional acti-
vation, enhancer-blocking and insulator properties and its inﬂu-
ence on chromatin organisation27, FOXO3 rs12206094 might
affect gene expression of neighboring genes or may even act
interchromosomally. Experimental evidence for this hypothesis
has recently been published44.
In eQTL databases, a higher FOXO3 mRNA expression was
observed in the presence of the rs12206094-T and rs4946935-A
longevity alleles for almost all signiﬁcant eQTLs in various tissues
(Supplementary Table 7, Supplementary Fig. 10). Overall, there is
support for a decline in FOXO3 expression during the aging
process13,45. Furthermore, down-regulation of FOXO3 was shown
to result in cell morphology changes consistent with senes-
cence46,47. In line with our results, a higher FOXO3 mRNA
expression was observed before for the longevity-associated G
allele of rs2802292 in human skeletal muscle biopsies16. These
ﬁndings, together with the higher promoter activity in our luci-
ferase assays, are in agreement with the observation that a higher
FOXO3 mRNA expression leads to longevity in model organ-
isms13. However, in a recent article by Peters et al.48 it was shown
that FOXO3 expression increases in human blood with age. It is
conceivable that FOXO3 expression is upregulated during aging
to compensate increases in stress caused by old age itself. These
heterogeneous observations highlight the complexity of FOXO3
regulation and may indicate tissue-speciﬁc and/or stress level-
and stimuli-dependent mechanisms. Further research is needed
to clarify how aging affects FOXO3 expression in detail and which
tissues play pivotal roles for longevity.
The longevity allele A of SNV rs4946935 shows a considerable
frequency difference between populations that is unlikely to have
been produced by genetic drift (Supplementary Table 8).
Although rs4946935-A represents the ancestral state, it is today
the minor allele in non-Africans. Our results suggest that bal-
ancing or diversifying selection may have played a role in the
global distribution of the rs4946935 alleles (and perhaps those of
rs12206094 as well). The respective selective pressures remain to
be identiﬁed, although past population admixture or bottleneck
events may also have left their footprint on the spatial allele
distribution. However, given the functional effects of rs4946935
and rs12206094 on IIS, a dietary inﬂuence seems probable.
For instance, European hunter-gatherers and early farmers
showed a much higher frequency of the rs12206094 longevity
allele (53.7% and 47.5%, respectively) than contemporary
Europeans49 (Supplementary Table 8). The same was observed
for a SNV in strong LD with rs4946935 (rs1935949; r2 = 0.96:
62.0% and 45.3%, respectively)49 (Supplementary Table 8), indi-
cating that the dietary shift during the Neolithic may have
led to an increase in the alternative alleles C and G. Interestingly,
in our promoter assays, the major alleles of both SNVs were
rather unresponsive to IGF-1 treatment, while the longevity
alleles were more susceptible and resulted in a lower promoter
activity. IGF-1 is particularly inducible by ingestion of insulino-
tropic dairy (e.g., milk)50, which likely started in the Neolithic
when people began to domesticate animals. Thus, the major
alleles may have enabled a sufﬁcient FOXO3 expression in the
presence of an IGF-1 overload that is caused by an animal
protein-rich diet. In contrast, the longevity alleles appear to be
more beneﬁcial under basal nutrient conditions and famine.
Similarly, changes of other metabolic genes in farming commu-
nities have been interpreted as successful adaptations to the new
Neolithic diets and life-style49.
Taken together, our study reveals hitherto undescribed
mechanistic and evolutionary aspects of the role of FOXO3 in
human longevity. Most genetic association ﬁndings involving
variants in non-coding regions have remained elusive so far.
Against this background, we here present ﬁrst experimental evi-
dence for a functional link between common intronic variants in
FOXO3 and the longevity phenotype in humans.
Methods
German, French and Danish study populations. The total German study
population comprised 515 unrelated nonagenarians and 594 centenarians (95–110
years, mean age 99.3 years). The male:female ratio in the sample was about 1:3.
The participants were recruited from different geographic regions of Germany and
were all of German ancestry. The 918 unrelated younger controls were 60 to 75
years old (mean age: 67.0 years) and were matched for ancestry, sex, and geo-
graphic origin within the country. The recruitment of the German sample was
partly organized by the PopGen biobank and has been described in detail else-
where51. All participants gave written informed consent to participate in the study.
Approval for the project was obtained from the Ethics Committee of the Medical
Faculty of Kiel University.
French centenarians were recruited when they were in their 100th year or
beyond52. French siblings were recruited when at least two siblings fulﬁlling the age
criterion of 90 years or older were alive in a family. The oldest sibling was selected
for the association study. The mean age of centenarians and the group of oldest
siblings drawn from each sib pair was 104 and 100 years, respectively (age at death
or age at last contact). In total, 1264 unrelated elderly were included in the study
(91–115 years, mean age 102.4 years; male:female ratio ~ 1:4.5). All subjects signed
a written informed consent form in accordance with the local review board Paris
Saint-Antoine. The 1830 French unrelated controls (35–62 years, mean age 49.1
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years) were selected in a population-based sample of French subjects that had
participated in the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.
MAX) study53.
The 643 unrelated Danish LLI (92–101 years; mean age 95.7 years; male:female
ratio ~ 1:3) were drawn from three population-based nation-wide birth cohort
studies conducted at the University of Southern Denmark: The Danish 1905 birth
cohort study, the Danish 1910 birth cohort study, and the Danish 1915 birth cohort
study54. Brieﬂy, the 1905 birth cohort study was initiated in 1998, when
participants were 92–93 years of age, and the 1910 and the 1915 Birth Cohort
Studies were initiated in 2010, when participants were 100 and 95 years of age,
respectively. The 746 unrelated younger controls (56–71 years, mean age 63.1 years;
male/female ratio ~ 1:1.5) were drawn from the Study of Middle Aged Danish
Twins (MADT)55. The sample partly overlapped with the one used in the study by
Soerensen et al.7. Written informed consent was obtained from all participants and
all studies were approved by The Regional Scientiﬁc Ethical Committees for
Southern Denmark.
Sequencing and genotyping. For sequencing and genotyping, genomic DNA was
extracted from EDTA whole blood (Invisorb Blood Universal Kit; STRATEC
Biomedical AG, Birkenfeld, Germany) and subjected to whole genome ampliﬁca-
tion (following the standard protocol of GenomiPhi V2 Amp Kit 500 RXS;
Amersham Biosciences; GE Healthcare Europe GmbH) prior to the genotyping
experiments. Three different sequencing approaches were applied: (1) sequencing
by ligation (SBL, SOLiD); (2) sequencing by synthesis (SBS, Illumina); and (3)
Sanger sequencing. Supplementary Table 1 provides an overview of the samples
used in the three sequencing approaches.
To avoid sequencing and genotyping errors that might derive from the FOXO3
pseudogene ZNF286B (99% sequence homology with exonic FOXO3 regions), we
consistently applied a published method to ensure FOXO3 speciﬁty in the highly
homologous exonic regions10. For SOLiD sequencing by ligation (SBL), 23 long-
range PCR fragments were generated to cover and enrich the whole ~ 170 kb
genomic FOXO3 region. Fragment libraries (50 bp single-end reads) were
constructed for 34 German centenarians (≥100 years), 16 younger German controls
(64–75 years), and six HapMap-CEU samples (Utah residents with Northern and
Western European ancestry; GM12752, GM12753, GM12755, GM11997,
GM10838, GM10839). Library preparation and sequencing were performed
according to Melum et al.56. The obtained reads were mapped using the default
parameters of the BioScope Software (Thermo Fisher Scientiﬁc Inc., Waltham,
USA) against the target region that was created using the FASTA NCBI36/hg18
reference sequence. Due to both poor coverage for parts of the FOXO3 gene and
problems in generating the long-range PCR fragments, some gaps remained in the
obtained reads (Supplementary Fig. 1a). Mapping of the obtained sequences against
the FASTA NCBI36/hg18 reference revealed that approximately 65% of the reads
were mapped for all individuals covering over 80% of the target region at 50×. The
sequence coverage was computed using the BedTools package57, the Genome
Analysis Toolkit58 (GATK), and the GATK´s CombineVariants58. SNVs were
detected using the software programs DiBayes (Thermo Fisher Scientiﬁc Inc.,
Waltham, USA) and SAMtools59. The variants were annotated with an in-house
pipeline. After annotation, false-positive SNV calls were removed with pibase60.
The sequences of all primers used for the generation of long-range products for the
SBL technology are listed in Supplementary Table 10.
For Illumina sequencing by synthesis (SBS), genomic DNA samples of 48
centenarians (≥ 100 years) und 46 younger controls (61–75 years) were subjected to
target enrichment61 using RainDance Technologies (RainDance Technologies, Inc.,
Billerica, MA, USA) to generate 349 fragments (300–600 bp; Supplementary
Data 3) that covered the whole FOXO3 region except for exons 3 and 4. For these
large exons, two long-range PCR amplicons (2704 bp and 5,523 bp, respectively;
Supplementary Table 11) were produced and sequenced to avoid contamination
with highly homologous ZNF286B reads10. Paired-end sequencing with 2 × 100 bp
reads was performed on the Illumina HiSeq 2000 (Illumina, San Diego, CA, USA)
according to the manufacturer’s instructions. The sequences were aligned to hg19
using Burrows–Wheeler Aligner with default parameters62. Sequence coverage was
analysed with the BedTools package57 and Picard (picard.sourceforge.net/). Base
calling and quality check after sequencing was done with the GA pipeline version
1.3 (support.illumina.com/downloads/pipeline_132.ilmn) and the FastQC package
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), respectively.
Mapping and variant-calling was performed as previously published63. Brieﬂy, to
prevent false-positive SNV calls at the end of sequencing reads and obtain accurate
scores on SNV calls, local realignment around indels and quality score recalibration
was done using GATK58, non-uniquely mapped reads were removed with
SAMtools59, duplicates were removed using Picard’s MarkDuplicates (picard.
sourceforge.net/), variant calling was performed with SAMtools59 and GATK58,
and the results were subsequently merged for further analysis using GATK’s
CombineVariants58. False-positive SNV calls were removed with pibase60 and
annotation was performed with an in-house pipeline.
In another set of 138 LLI (mean age: 101.5 years) and 92 controls (60–75 years),
Sanger sequencing (Thermo Fisher Scientiﬁc, Waltham, Massachusetts, US) was
performed for all four exons, the exon-intron boundaries, and the promoter of
FOXO3 transcripts NM_201559 and NM_001455 to provide additional
information on these important regions. Prior to sequencing, 24 PCR amplicons
were generated for the investigated FOXO3 region. For the two large exons (exon 3
and exon 4), FOXO3-speciﬁc long-range products were used as templates. SNVs
were detected and visualized with the software packages novoSNV64 and InSNP65.
The sequences of all primers used for FOXO3 Sanger sequencing and the
generation of long-range products for exon 3 and exon 4 are listed in
Supplementary Table 11.
SNV selection. For extensive ﬁne mapping, altogether 205 SNVs located in the
FOXO3 gene region were genotyped and analyzed in a German case–control
association study for longevity. The typed SNVs were mainly selected through a
haplotype-tagging approach (based on the HapMap genotypes of Europeans
applying Haploview 4.2 (http://www.broad.mit.edu/mpg/haploview/)) to ensure
that most of the allelic variation of the genomic regions was captured and the
common haplotypes were represented. In addition, SNVs that were located in
regulatory regions (microRNA binding sites, methylation sites, enhancer sites,
transcription factor-binding sites, degree of conservation, and Dnase I hypersen-
sitive sites) were selected. Furthermore, all detected common and rare SNVs in
coding and non-coding exonic regions (n = 28) were selected for genotyping due to
the functional relevance of these regions. The bioinformatic tools and databases
used for SNV selection are listed in the footnote of Supplementary Data 2. For
further information on the variants, we applied in silico analysis to the SNVs in the
coding exons 2 and 3 with various bioinformatic tools (Supplementary Table 12).
For the non-coding exonic SNVs in exon 4, MutationTaster225 was used (Sup-
plementary Table 13). Altogether, no functional relevance was detected for any of
the exonic SNVs that were associated with longevity in our data.
For the four SNVs in exon 2, no FOXO3-speciﬁc long-range products could be
generated. Two of the four detected SNVs (rs150320900 and snv_chr6_108989376)
showed a very low MAF (MAF ≤ 0.001) and were excluded from the case–control
study as the low MAF precluded any meaningful statistical power for association
studies. SNV rs11757217 was not considered either for further analysis as the
generated FOXO3-speciﬁc sequencing data showed a frequency difference of less
than 2% between 170 centenarians and 136 younger controls. For rs111556510,
suitable SNVs in strong LD (r2> 0.8) located in the intronic region (rs77626104,
rs111254195, rs113032762) were selected for genotyping instead.
Genotyping. Genotyping of the German, French and Danish samples was per-
formed either by TaqMan (Thermo Fisher Inc., Waltham, Massachusetts, USA) or
iPLEX (Sequenom; San Diego, CA, USA) technology. TaqMan genotyping was
carried out on a 7900HT Fast Real-time PCR System (Thermo Fisher Scientiﬁc
Inc., Waltham, MA, USA). The sequenom genotyping was done on a MassARRAY
Analyzer 4 System (Sequenom, Hamburg, Germany). Sequenom assays were
designed using the Human Genotyping Tool (https://www.mysequenom.com/
Tools) and the Typer Analyzer 4.0 Software (Sequenom, Hamburg, Germany).
FOXO3-speciﬁc long-range PCR products served as PCR-templates for SNVs
located in exon 3 and 4. Part of the Danish sample was genotyped on the Illumina
HumanOmniExpress BeadChips (Illumina Inc., San Diego, CA, USA) followed by
imputation using the 1000 G Phase I Integrated Release Version 3 reference panel
and the IMPUTE2 program66.
Analysis of transcription factor-binding sites. For the detection of allele-speciﬁc
transcription factor-binding sites, intronic FOXO3 regions containing the allelic
variants of rs4946935 and rs12206094 were analyzed using HaploReg v4.124 (www.
broadinstitute.org/mammals/haploreg/), RegulomeDB25 (http://regulome.stanford.
edu/), sTRAP23 (http://trap.molgen.mpg.de/cgi-bin/trap_two_seq_form.cgi), and
the CTCF binding site database (CTCFBSDB) 2.0 (http://insulatordb.uthsc.edu/)27.
Construction of plasmids. The reporter plasmids pGL3_rs4946935-G for the
major allele and pGL3_rs4946935-A for the minor allele were generated by the
insertion of a 134-bp region into the pGL3 promoter vector (Promega, Madison,
WI, USA) upstream of the promoter-luciferase transcriptional unit using speciﬁc
primers in accordance with the NEB Q5 site-directed mutagenesis protocol
(New England BioLabs, Ipswich, MA). pGL3_rs12206094-T (minor allele)
was constructed by inserting an 80 bp region using the same strategy. For
pGL3_rs12206094-C (major allele) primers with a substitution of the minor
allele (TTG CTA CCA) to the major allele (TTG CCA CCA) were designed.
The major allele was inserted by using the QuickChange Side-directed Mutagenesis
Kit (Stratagene, La Jolla, USA) according to the manufacturer´s instructions.
All constructs were veriﬁed by DNA sequencing. The plasmid DNA was puriﬁed
using the Plasmid Midi Kit (Invitrogen, Carlsbad, CA, USA). The sequences of
all primers used in the generation of the plasmids are listed in Supplementary
Table 14.
Electrophoretic mobility shift assay and supershift assay. The human cell lines
Panc1 (ATCC via LGC Standards, Wesel, Germany) and Jurkat (kindly provided
by Prof. Hendrik Ungefroren, Department of Internal Medicine I, University
Hospital Schleswig-Holstein, Campus Lübeck) were maintained at 37 °C, 85%
humidity and 5% CO2 in RPMI1640 medium supplemented with 10% FCS, 1%
L-glutamine. The cell culture media for Panc1 cells was additionally supplemented
with 1% sodium pyruvate. Cells were tested regularly by MycoAlert Mycoplasma
Detection Kit (Lonza, Cologne, Germany). Preparation of nuclear extracts was
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done as described previously67. For gel-shift assays, 5 µg of nuclear extracts were
incubated with 32P-labeled oligonucleotides (Supplementary Table 14) spanning
the allele-speciﬁc putative transcription factor-binding sites (or a known consensus
sequence (STAT5A, sc-2565; Santa Cruz, Heidelberg, Germany)) of the indicated
transcription factors. For supershift experiments, 4 µg of antibody (anti-SRF
(sc335x), anti-PDX1 (sc14664x, goat), anti-STAT5A (sc1081x), anti-CTCF
(sc271474x), all Santa Cruz, Heidelberg, Germany; anti-PDX1 (5679x, rabbit), anti-
IgG (2729, rabbit), both New England Biolabs GmbH, Frankfurt a.M., Germany);
anti-IgG (Merck Chemicals GmbH, Darmstadt, Germany)) were additionally
added to the reaction mix 30 min prior to electrophoresis and incubated at 4 °C.
After separation by gel electrophoresis (100 V, 4 °C), gels were dried and exposed to
X-ray Hyperﬁlm (Amersham, Freiburg, Germany). Densitometry of the CTCF-
speciﬁc band against immunoglobulin G (IgG) was performed using the ImageJ
software (https://imagej.nih.gov/ij/).
Luciferase assay. To analyze the impact of the different alleles on transcriptional
activity, 3 × 104 Panc1 or Jurkat cells were seeded into each well of a 48-well plate
(Greiner, Frickenhausen, Germany). For this, cells were resuspended in 500 µL
RPMI-complete medium (RPMI-1640 supplemented with 10 % fetal calf serum
(FCS), 1 % L-glutamine and 1 % sodium pyruvate, all purchased from Biochrom
(Biochrom GmbH, Berlin, Germany)). After culturing overnight, the medium was
removed and the cells were transfected with 80 ng per well of either of the ﬁreﬂy
constructs together with 40 ng per well of pRL-TK (reporter vector for normal-
ization using Renilla luciferase controlled by the herpes simplex virus thymidine
kinase (HSV-TK) promoter; Promega, Mannheim, Germany) using the Effectene
Transfection Reagent according to the instruction of the manufacturer (Qiagen,
Hilden, Germany). The following ﬁreﬂy plasmids were used: pGL3-rs4946935-A
(containing the minor allele (A)), pGL3-rs4946935-G (containing the major allele
(G)), pGL3-rs12206094-T (containing the minor allele (T)) or pGL3-rs12206094-C
(containing the major allele (C)). After an incubation period overnight, the cell
culture medium was changed with cells being either cultured in RPMI-1640
complete medium (+FCS) or in RPMI-1640 medium lacking FCS (-FCS). Addi-
tionally, cells were treated either with 1 µl EGCG (Sigma-Aldrich Chemie Gmbh,
Munich, Germany) at a concentration of 50 µM and an equal volume of DMSO as
control, respectively, with 100 ng/mL IGF-1 (Merck, Darmstadt, Germany) or with
1 or 10 µg/mL insulin (Sigma-Aldrich Chemie Gmbh, Munich, Germany). After
48 h, cells were washed once with PBS and lysed for measurement of luciferase
activity using the Dual-Luciferase Reporter Assay System according to the man-
ufacturer’s instructions (Promega, Mannheim, Germany). All measurements were
performed with a Tecan Inﬁnite M200 PRO luminometer (Tecan, Crailsheim,
Germany). For determination of speciﬁc luciferase activity, activity of the ﬁreﬂy
luciferase was normalized to the activity of the renilla luciferase.
siRNA-mediated knockdown. To suppress expression of CTCF and SRF in
Panc1 cells for luciferase assays, 1 × 105 Panc1 cells per well were seeded in 12-well-
plates containing 1 mL medium per well. After 24 h, medium was removed and
1 mL fresh medium was added. Then, 6 µL per well HiperFect reagent (Qiagen,
Hilden, Germany) and 2.5 µL of either negative control siRNA (sc-37007, Santa
Cruz) or speciﬁc siRNA against SRF (sc-36563, Santa Cruz) or CTCF (sc-35124;
Santa Cruz), all in a concentration of 25 nM, were mixed with 100 µL FCS-free
medium and added to cells. After 72 h, cells were detached, seeded and transfected
and treated for luciferase assay as described above.
RNA isolation and RT-qPCR. Knockdown of CTCF and SRF was veriﬁed by RT-
qPCR. For this purpose, total RNA of siRNA transfected Panc1 cells was isolated
with the total RNA kit peqGOLD (PeqLab, Erlangen, Germany) and subjected to
reverse transcription according to the manufacturer’s instructions (Fermentas, via
Thermo Fisher Scientiﬁc, Darmstadt, Germany). CTCF and SRF primers were
purchased from Microsynth AG (Lindau, Germany) and GAPDH primers from
Euroﬁns (Ebersberg, Germany). Primer sequences are: CTCF FW: 5′-TCTGA-
CAGTGAAAATGCTGA-3′; RV: 5′-TCTGGTCTTCAACCTGAATG-3′; GAPDH
FW: 5′-TCCATGACAACTTTGGTATCGTGG-3′; RV: 5′-GACGCCTGCTT-
CACCACCTTCT-3′; SRF FW: 5′-CTCAACTCGCCAGACTCTCC-3′; RV: 5′-
CCGGCTT-CAGTGTGTCCTTG-3′. Primer speciﬁcity was tested by melting curve
analysis and veriﬁcation of PCR product size. All PCRs were performed as
duplicates with a LightCycler 480 (Roche, Mannheim, Germany) for 50 cycles
followed by a melting curve analysis. The amount of RNA of the gene of interest
was normalized to the RNA amount of the control gene GAPDH.
Analysis of tissue-speciﬁc expression patterns. Tissue- and cell type-speciﬁc
expression patterns of FOXO3, SRF, STAT5A, CTCF, and PDX1 were analysed by
endpoint-PCR. Analyzed cDNAs of human tissues (brain, heart, lung, skeletal
muscle, spleen, thymus, liver, kidney, pancreas, duodenum, jejunum, colon, bone
marrow, ovaries and testis) were purchased from Takara Bio Europe SAS (Saint-
Germain-en-Laye, France). cDNAs of the investigated cell lines (Panc1; Jurkat;
human colon adenocarcinoma cell line, HT-29; human embryonic kidney cell line,
HEK; human epithelial carcinoma cell line, Hela) were prepared using standard
methods. GAPDH was used as endogenous control. Primer sequences for the
speciﬁc ampliﬁcation of FOXO3, SRF, STAT5A, CTCF, and PDX1 are listed in
Supplementary Table 14. Ampliﬁed PCR products were separated on a 1% agarose
gel and visualized using the Universal Hood II (Biorad, München, Germany).
eQTL analysis. For the two best-associated FOXO3 SNVs rs12206094 and
rs4946935 as well as for SNVs in LD with r2> 0.8 (based on HapMap-CEU
individuals, 1000 Genomes21,22), signiﬁcant cis eQTL associations in whole blood
and various tissues were looked up in the publicly available databases GTEx (http://
www.gtexportal.org/home/) and Blood eQTL browser29 (http://genenetwork.nl/
bloodeqtlbrowser/). Using the “Test Your Own SNP-Gene Associations” section of
the GTEx database, we computed associations between FOXO3 mRNA expression
and rs12206094 or rs4946935 in all tissues available without Q-value ﬁltering.
In silico promoter analysis. In silico promoter analysis of the human IGF-1
promoter was performed using the MatInspector analysis tool of the Genomatix
software41 (https://www.genomatix.de/cgi-bin/matinspector_prof/).
Statistical analyses. Univariate statistical analysis of the case–control studies was
performed using PLINK v.1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/)
software. Allelic P values were calculated using the Chi square test with P values ≤
0.05 being considered nominally signiﬁcant. Odds ratios are always based on minor
alleles in controls. SNVs were tested for Hardy–Weinberg equilibrium in the
control group with a signiﬁcance level of 0.001. The LD information was based on
HapMap and 1000 Genomes data using the SNAP Proxy Search function21,22
(https://archive.broadinstitute.org/mpg/snap/ldsearch.php).
Additionally, we performed logistic regression analysis with longevity as
outcome and SNVs as inﬂuence variables with the statistical software R, version
3.2.2 (http://www.R-project.org/)68. Genotypic (saturated), allelic, dominant, or
recessive effects were used for the coding of the SNVs. Since no clear superiority of
dominant or recessive modelling could be detected, the genotypic and allelic coding
was applied. The SNVs were tested as single inﬂuence variables as well as jointly
(with and without interaction). Additionally, we tested for an interaction of sex and
SNV effect. Because of the logistic regression approach, a signiﬁcant interaction
between two variables means that the joint OR of the two variables is unequal to
the multiplication of the single ORs of the variables. Because of a larger and more
reliable sample size for the interaction in the allelic model vs. the genotypic one, the
resulting allelic ORs are displayed in Table 2.
For a meta-analysis of rs4946935 and rs12206094, we combined the data from
the German, French and Danish studies. For the German study, the centenarians
and not the LLI were used as cases. A logistic regression was performed and
adjusted for population. No signiﬁcant interaction between population and SNV
effect was found. Additionally, we tested for an interaction between sex and variant,
adjusting for population and sex.
All statistical analyses for rs4946935, rs12206094, and age-related phenotypes
(Supplementary Tables 2–5) in Danish LLI and controls were performed using the
statistical software Stata (Stata version 14.2; Stata Corporation, College Station, TX,
USA). Linear regression was used for the analysis of age at ﬁrst child, age at last
child, age at menopause, timed chair stand, cognitive composite score, grip
strength, and number of biological children. Ordinal logistic regression
(proportional odds model) was used for the analysis of chair stand and Mini-
Mental-State-Examination. All analyses were adjusted for age at assessment
and sex.
Population genetic inferences were based on the Pilot 1 data from the 1000
Genomes Project22, available from the International Genome Sample Resource
(IGSR; http://www.internationalgenome.org/). Tajima’s D values and FST estimates
following Weir & Cockerham69 were obtained from the dbPSHP database
resource30 (http://jjwanglab.org/dbpshp).
For the statistical analysis of the luciferase experiments, the two-sided Wilcoxon
signed-rank test for paired data was applied. A signiﬁcance level of 0.05 was
chosen. Calculations were performed in SPSS, version 22. For graphical display,
values were normalized.
In total, 205 SNVs from the sequencing experiments were selected for
association testing in the German longevity sample of 1109 cases and 918 controls.
For an OR of 1.3 and a two-sided test of difference of proportions between cases
and controls, this results in a power between 46% (MAF in cases = 0.10) and 84%
(MAF in cases = 0.50) for a signiﬁcance level of 0.05. Since FOXO3 is already an
established longevity gene and the aim of our study was to identify functional
variants and not to validate the association, adjustment for multiple testing was not
performed.
The variants rs12206094 and rs4946935 were later tested for association also in
the French and Danish longevity sample (French: ncases = 1264, ncontrols = 1830,
Danish: ncases = 643, ncontrols = 746). For rs12206094 with a minor allele
frequency of 0.325 in cases and an OR of 1.3, this results in a power of 93% in the
French and of 64% in the Danish sample (signiﬁcance level of 0.05). For
rs4946935 with a minor allele frequency of 0.349 in cases and an OR of 1.3, the
corresponding power is 94% in the French and 66% in the Danish sample
(signiﬁcance level of 0.05). Power calculations were performed with G*Power,
version 3.1.9.270.
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Data availability. All samples and information on their corresponding phenotypes
were obtained from the PopGen Biobank (Schleswig-Holstein, Germany) and can
be accessed through a Material Data Access Form. Information about the Material
Data Access Form and how to apply can be found at http://www.uksh.de/p2n/
Information + for + Researchers.html.
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